ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - water for injections, quantity: 40 ml - injection, solution - excipient ingredients: - treatment and perioperative prophylaxis of bleedings in acquired deficiency of the prothrombin complex coagulation factors, such as deficiency caused by treatment with vitamin k antagonists, or in case of overdose of vitamin k antagonists, when rapid correction of the deficiency is required.

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

mallinckrodt hospital products inc. - thrombin alfa (unii: sck81amr7r) (thrombin alfa - unii:sck81amr7r) - thrombin alfa 1000 [iu] in 1 ml - recothrom® thrombin topical (recombinant), is a topical thrombin indicated to aid hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques (such as suture, ligature, or cautery) is ineffective or impractical in adults and pediatric populations greater than or equal to one month of age. recothrom may be used in conjunction with an absorbable gelatin sponge, usp. - do not inject directly into the circulatory system. - do not use for the treatment of massive or brisk arterial bleeding. - do not administer to patients with a history of hypersensitivity to recothrom or any components of recothrom. - do not use in patients with known hypersensitivity to hamster proteins. pregnancy category c animal reproduction studies have not been conducted with recothrom. it is also not known whether recothrom can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. recothrom should be given

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

the medicines company - thrombin alfa (unii: sck81amr7r) (thrombin alfa - unii:sck81amr7r) - thrombin alfa 1000 [iu] in 1 ml - recothrom ®, thrombin topical (recombinant), is a topical thrombin indicated to aid hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques (such as suture, ligature, or cautery) is ineffective or impractical in adults and pediatric populations greater than or equal to one month of age. recothrom may be used in conjunction with an absorbable gelatin sponge, usp. - do not inject directly into the circulatory system. - do not use for the treatment of massive or brisk arterial bleeding. - do not administer to patients with a history of hypersensitivity to recothrom or any components of recothrom. - do not use in patients with known hypersensitivity to hamster proteins. pregnancy category c animal reproduction studies have not been conducted with recothrom. it is also not known whether recothrom can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. recothrom should be give

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

csl behring gmbh - prothrombin (unii: 8fb1k07f16) (prothrombin - unii:8fb1k07f16), coagulation factor vii human (unii: 4156xvb4qd) (coagulation factor vii human - unii:4156xvb4qd), coagulation factor ix human (unii: 6u90y1795t) (coagulation factor ix human - unii:6u90y1795t), coagulation factor x human (unii: 0p94uqe6sy) (coagulation factor x human - unii:0p94uqe6sy), protein c (unii: 3z6s89txpw) (protein c - unii:3z6s89txpw), protein s human (unii: 90j3f6n5fn) (protein s human - unii:90j3f6n5fn) - prothrombin 590 u in 20 ml - kcentra, (prothrombin complex concentrate (human)), is a blood coagulation factor replacement product indicated for the urgent reversal of acquired coagulation factor deficiency induced by vitamin k antagonist (vka, e.g., warfarin) therapy in adult patients with: - acute major bleeding or - need for an urgent surgery/invasive procedure. kcentra is contraindicated in: - patients with known anaphylactic or severe systemic reactions to kcentra or any components in kcentra including heparin, factors ii, vii, ix, x, proteins c and s, antithrombin iii and human albumin. - patients with disseminated intravascular coagulation (dic). - patients with known heparin-induced thrombocytopenia (hit). kcentra contains heparin [see description (11)] . risk summary there are no data with kcentra use in pregnancy to inform on drug-associated risk. animal reproduction studies have not been conducted with kcentra. it is not known whether kcentra can cause fetal harm when administered to a pregnant woman or can affect reproduction

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - water for injections, quantity: 20 ml - injection, solution - excipient ingredients: - treatment and perioperative prophylaxis of bleedings in acquired deficiency of the prothrombin complex coagulation factors, such as deficiency caused by treatment with vitamin k antagonists, or in case of overdose of vitamin k antagonists, when rapid correction of the deficiency is required.

माल्टा - अंग्रेज़ी - Medicines Authority

csl behring gmbh emil-von-behring-strasse 76, 35041 marburg, germany - human fibrinogen - powder for solution for injection/infusion - human fibrinogen 1 g - antihemorrhagics

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

octapharma usa inc - fibrinogen human (unii: n94833051k) (fibrinogen human - unii:n94833051k) - fibryga is a human fibrinogen concentrate indicated for the treatment of acute bleeding episodes in adults and children with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia. fibryga is not indicated for dysfibrinogenemia. fibryga is contraindicated in individuals who have manifested severe immediate hypersensitivity reactions, including anaphylaxis, to fibryga or its components (sodium citrate dihydrate; glycine; l-arginine hydrochloride). risk summary there are no data with fibryga use in pregnant women to determine whether there is a drug-associated risk. animal reproduction studies have not been conducted with fibryga. it is not known whether fibryga can cause fetal harm when administered to a pregnant woman or can affect fertility. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. risk summary there is no information regarding the presence of fibryga

आयरलैंड - अंग्रेज़ी - HPRA (Health Products Regulatory Authority)

octapharma (ip) sprl - human fibrinogen - powder and solvent for solution for injection/infusion - 1 gram(s) - fibrinogen, human

कनाडा - अंग्रेज़ी - Health Canada

corza medical gmbh - thrombin (human); collagen; fibrinogen (human) - patch - 2unit; 2.1mg; 5.5mg - thrombin (human) 2unit; collagen 2.1mg; fibrinogen (human) 5.5mg - hemostatics

कनाडा - अंग्रेज़ी - Health Canada

corza medical gmbh - thrombin (human); collagen; fibrinogen (human) - patch - 2unit; 2.1mg; 5.5mg - thrombin (human) 2unit; collagen 2.1mg; fibrinogen (human) 5.5mg - hemostatics